Trials / Completed
CompletedNCT01193296
Glycemic Holter Study (Continuous Glucose Monitoring) -
Prospective, Randomized, Open-label Study With Blinded Endpoint (PROBE Design) to Compare the 72 hr Glycemic Profiles Obtained by Continuous Subcutaneous Glucose Monitoring (CSGM) in Type 2 Diabetic Patients at Baseline With Metformin Monotherapy and After an 8-week Period With the Addition of Either Vildagliptin or Sitagliptin in Patients Insufficiently Controlled by Metformin After at Least 3 Months of Monotherapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The study will assess glycemic variability and optimized glycemic control in T2DM patients treated with a DPP-4 inhibitor as add-on therapy to metformin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin | |
| DRUG | Sitagliptin |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2010-09-01
- Last updated
- 2012-05-04
Locations
7 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01193296. Inclusion in this directory is not an endorsement.